Luciana Catanese
A5075596562- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Stroke Rehabilitation and Recovery
- Venous Thromboembolism Diagnosis and Management
- Long-Term Effects of COVID-19
- Peripheral Artery Disease Management
- Neurosurgical Procedures and Complications
- COVID-19 and healthcare impacts
- Atrial Fibrillation Management and Outcomes
- Traumatic Brain Injury and Neurovascular Disturbances
- Retinal and Optic Conditions
- Intracranial Aneurysms: Treatment and Complications
- S100 Proteins and Annexins
- Health Systems, Economic Evaluations, Quality of Life
- Neurological Disease Mechanisms and Treatments
- Adolescent and Pediatric Healthcare
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood Pressure and Hypertension Studies
- Cardiovascular Health and Disease Prevention
- Climate Change and Health Impacts
- Dementia and Cognitive Impairment Research
- Cardiac Imaging and Diagnostics
- COVID-19 Clinical Research Studies
- Diversity and Career in Medicine
Hamilton Health Sciences
2017-2025
McMaster University
2017-2025
Population Health Research Institute
2017-2025
University of Calgary
2024
Health Sciences Centre
2022-2024
United Nations Economic and Social Commission for Asia and the Pacific
2021-2024
University of Ottawa
2024
University of Manitoba
2024
Ottawa Hospital
2024
Université de Montréal
2024
Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies). We present detailed analyses stroke type, predictors, and antithrombotic effects key subgroups.Participants had stable coronary artery or peripheral disease randomly assigned to receive 100 mg once daily (n=9126), 5 twice (n=9117), 2.5 (n=9152). Patients who required anticoagulation a within 1 month, previous...
It is unknown whether intravenous thrombolysis using tenecteplase noninferior or preferable compared with alteplase for patients acute ischemic stroke.
<h3>Importance</h3> The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized clinical trial was stopped early owing to the efficacy of low-dose rivaroxaban plus aspirin in preventing major cardiovascular events. main reason termination effect combination therapy on reducing ischemic strokes. <h3>Objective</h3> To analyze association between with or without and different stroke subtypes. <h3>Design, Setting, Participants</h3> This is a secondary analysis...
<h3>Background and Objectives</h3> Declines in stroke admission, IV thrombolysis (IVT), mechanical thrombectomy volumes were reported during the first wave of COVID-19 pandemic. There is a paucity data on longer-term effect pandemic over course year through second We sought to measure admissions, intracranial hemorrhage (ICH), IVT, 1-year period at onset (March 1, 2020, February 28, 2021) compared with immediately preceding 2019, 29, 2020). <h3>Methods</h3> conducted longitudinal...
We investigated the impact of regionally imposed social and healthcare restrictions due to coronavirus disease 2019 (COVID-19) time metrics in management acute ischemic stroke patients admitted at regional referral site for Central South Ontario, Canada.We compared relevant between with receiving intravenous tissue plasminogen activator (tPA) and/or endovascular thrombectomy (EVT) before after declared state emergency our region (March 17, 2020).We identified a significant increase median...
BACKGROUND: Data on systolic blood pressure (SBP) trajectories in the first 24 hours after endovascular thrombectomy (EVT) acute ischemic stroke are limited. We sought to identify these and their relationship outcomes. METHODS: combined individual-level data from 5 studies of patients with who underwent EVT had individual values end procedure. used group-based trajectory analysis number shape SBP post-EVT. mixed effects regression models associations between groups outcomes adjusting for...
Objective To characterize cerebral microbleeds (CMBs) in lacunar stroke patients the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess their relationship with recurrent death, response assigned treatment. Methods SPS3 is a randomized, clinical conducted between 2003 2011. Patients recent magnetic resonance imaging (MRI)‐documented infarcts were randomly factorial design target levels systolic blood pressure (130–149mmHg vs <130mmHg; open label) antiplatelet...
Background and Objectives: Emerging literature suggests that non-stenotic carotid disease (<50% stenosis), especially in the presence of high-risk plaque features, can be a possible etiology for ischemic stroke. We aimed to evaluate odds concordant stroke among individuals with arteries various features. Methods: This is secondary analysis from Alteplase compared Tenecteplase (AcT) trial. evaluated on baseline CT Angiogram (CTA) assess degree stenosis, features such as ulceration,...
Background and Objectives: Transportation to comprehensive stroke centers (CSCs) from primary (PSCs) is key achieving fast reperfusion in endovascular treatment (EVT)-eligible patients. We aimed evaluate outcomes workflow times of patients treated PSCs vs CSCs additional metrics for those transported EVT. Methods: performed a pre-specified analysis the Alteplase compared Tenecteplase (AcT) multicenter, randomized, controlled, trial with acute ischemic within 4.5 hours onset. baseline...
Background: Telestroke allows rapid assessment of patients presenting with acute stroke symptoms for intravenous thrombolysis or endovascular thrombectomy (EVT). Although the safety and efficacy telestroke services delivery has been well established, evidence on EVT decision-making is scarce. Methods: We analysed data from OPTIMISE, a quality improvement registry to support implementation in Canada. assessed unadjusted differences baseline characteristics, time metrics, procedural outcomes...
Introduction: The tenecteplase versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2) trial showed that patients presenting deficits up to 12 h do not benefit from intravenous thrombolysis. included but disabling deficits, mainly beyond 4.5 h, if they were eligible standard-of-care We aimed determine improves outcomes in this subgroup TEMPO-2 deficits. Methods: This was an exploratory secondary analysis the trial, which randomized across 48 hospitals globally acute...
Introduction Fast delivery of intravenous thrombolysis (IVT) and transportation to a comprehensive stroke center (CSC) is paramount in primary centers (PSCs), achieve effective reperfusion. We investigated clinical outcomes workflow times patients treated with IVT at PSCs. Methodology This secondary analysis the AcT trial, multicenter, phase-3, randomized, controlled, noninferiority trial comparing tenecteplase alteplase acute ischemic within 4.5 hours onset. compared baseline...
BACKGROUND: Older age has been associated with overall poorer outcomes in acute ischemic stroke. We compared (1) various health-related domains among patients <80 years and ≥80 presenting stroke (2) whether differ between intravenous TNK (tenecteplase) versus alteplase. METHODS: Data are from included AcT (Alteplase Compared to Tenecteplase Patients With Acute Ischemic Stroke), a pragmatic, registry-linked, phase 3 randomized controlled trial comparing Outcomes functional disability (per...